When Prescribing Isn't Enough - Pharmacy-Level Barriers to Buprenorphine Access

N Engl J Med. 2020 Aug 20;383(8):703-705. doi: 10.1056/NEJMp2002908.

Authors

Hannah L F Cooper¹, David H Cloud¹, April M Young¹, Patricia R Freeman¹

Affiliation

¹ From the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health at Emory University, Atlanta (H.L.F.C., D.H.C.); and the Department of Epidemiology, University of Kentucky College of Public Health (A.M.Y.) and the Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy (P.R.F.) - both in Lexington.

PMID: 32813945
DOI: 10.1056/NEJMp2002908

No abstract available

MeSH terms

Appalachian Region
Buprenorphine / supply & distribution*
Buprenorphine / therapeutic use
Health Policy*
Health Services Accessibility / statistics & numerical data*
Humans
Interprofessional Relations
Legislation, Drug*
Medical Overuse / legislation & jurisprudence
Narcotic Antagonists / supply & distribution*
Narcotic Antagonists / therapeutic use
Opiate Substitution Treatment*
Opioid-Related Disorders / drug therapy*
Pharmacies*
Pharmacists
Physicians
Stereotyping
Trust
United States
United States Government Agencies

Substances

Narcotic Antagonists
Buprenorphine